"It felt the way I thought my body should have been operating the entire time, says Field, who adds that she has dealt with constant food cravings and binge eating since childhood. Field, now age 43, had lost more than 100 pounds in two and a half years, and she says that the relief from food noise, a constant preoccupation with food, changed her life."
"Like Field, many people who have taken these drugs, broadly known as glucagonlike peptide 1 (GLP-1) receptor agonists, have seen weight loss stagnateand nearly a quarter haven't seen any weight or health benefits at all. So pharmaceutical companies are racing to make the next generation of these weight-loss treatmentsones that simultaneously target up to three food-related pathways in the brain."
Terra Field experienced marked satiety and lost over 100 pounds on Wegovy, then hit a plateau and resumed weight loss after switching to Zepbound. Many users of GLP‑1 receptor agonists have variable responses: some see significant declines, others experience stagnation, and nearly a quarter report no weight or health benefits. Pharmaceutical companies are developing next‑generation therapies that target two or three brain pathways involved in appetite. A gray market for unofficial versions of the drugs has emerged. New candidates are advancing through clinical trials and FDA reviews, while clinicians express concern that rapid or excessive weight loss can harm health.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]